TAK-285は一種の新たで、HER2とEGFR(HER1)二重阻害剤で、IC50値が17 nMと23 nMです。TAK-285は、HER1/2に作用する選択性はHER4に作用する選択性より10倍以上が高くなリますが、MEK1/5、c-Met、Aurora B、Lck、CSK等に作用する効果が少し弱いです。臨床1期。

価格 在庫  
USD 340 あり
USD 592 あり

TAK-285 化学構造
分子量: 547.96




  • Compare EGFR Inhibitors
  • 研究分野



製品説明 TAK-285は一種の新たで、HER2とEGFR(HER1)二重阻害剤で、IC50値が17 nMと23 nMです。TAK-285は、HER1/2に作用する選択性はHER4に作用する選択性より10倍以上が高くなリますが、MEK1/5、c-Met、Aurora B、Lck、CSK等に作用する効果が少し弱いです。臨床1期。
ターゲット HER2 EGFR
IC50 17 nM 23 nM [1]
In vitro試験 Among the 34 kinases tested, TAK-285 only significantly inhibits HER4 with IC50 of 260 nM, slightly inhibits MEK1, MEK5, c-Met, Aurora B, Lck, CSK, and Lyn B with IC50 of 1.1 μM, 5.7 μM, 4.2 μM, 1.7 μM, 2.4 μM, 4.7 μM, and 5.2 μM, respectively, and displays no activity against other kinases with IC50 of >10 μM. TAK-285 shows significant growth inhibitory activity against BT-474 cells (HER2-overexpressing human breast cancer cell line) with GI50 of 17 nM. [1] Compared with SYR127063 a potent inhibitor of HER2, TAK-285 displays similar in vitro potency against HER2 and EGFR. Compared with the full cytoplasmic domains of the wild-type proteins, the mutations and shortened boundaries used for structure determination of HER2-KD and EGFR-KD do not significantly change the inhibitory activity (IC50) of TAK-285. TAK-285 binds to the inactive conformation of EGFR, and shows a similar binding mode with lapatinib in the active site. [2]
In vivo試験 The oral bioavailability of TAK-285 is 97.7% in rats and 72.2% in mice at a dose of 50 mg/kg. Oral administration of TAK-285 at 100 mg/kg twice daily for 14 days displays significant antitumor efficacy in the HER2-overexpressing BT-474 tumor xenograft mouse model with tumor/control (T/C) ratio of 29%, without affecting body weight. Similar to the BT-474 model, TAK-285 exhibits dose-dependent tumor growth inhibition of 4-1ST (HER2-overexpressing human gastric cancer tumor) xenografts in mice, with T/C of 44% and 11% at doses of 50 mg/kg and 100 mg/kg, twice daily, respectively, without significant body weight loss in mice. Furthermore, TAK-285 treatment induces dose-dependent growth inhibition of 4-1ST tumors in rats with T/C of 38% and 14% at doses of 6.25 mg/kg and 12.5 mg/kg, and, particularly noteworthy, tumor regression with T/C of -12% and -16% at doses of 25 mg/kg and 50 mg/kg, respectively. [1] After oral administration of TAK-285, a significant amount of TAK-285 is present in the brain of rats in pharmacologically active, unbound form (approximately 20% of its free plasma level), indicating that TAK-285 has a potential in the therapy of CNS malignancies/metastases. [3]
臨床試験 A Phase I study of TAK-285 in patients with advanced cancer has been completed.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

HER2 and EGFR kinase assay The cytoplasmic domain (amino acids 676-1255) of human HER2 and the cytoplasmic domain (amino acids 669-1210) of human EGFR are expressed as N-terminal peptide (DYKDDDD)-tagged protein using a baculovirus expression system. The expressed HER2 kinase and EGFR kinase are purified by anti-FLAG M2 affinity gel. The EGFR and HER2 kinase assays are performed using radiolabeled [γ-32P]ATP in 96-well plates. The kinase reactions are performed in 50 mM Tris-HCl (pH 7.5), 5 mM MnCl2, 0.01% Tween 20, and 2 mM DTT containing 0.9 uCi of [γ-32P]ATP per reaction, 50 μM ATP, 5 ug/mL poly(Glu)-Tyr (4:1), and each purified cytoplasmic domain (0.25 μg/mL EGFR or HER2) in a total volume of 50 μL. To measure the IC50 value for enzyme inhibition, Increasing concentrations of TAK-285 are incubated with the enzyme for 5 minutes prior to the reaction at room temperature. The kinase reactions are initiated by adding ATP. After 10 minutes at room temperature, the reactions are stopped by the addition of 10% (final concentration) trichloroacetic acid. The γ-32P phosphorylated proteins are filtrated in a harvest plate with a cell harvester and washed free of [γ-32P]ATP with 3% phosphoric acid. The plates are dried followed by the addition of 25 μL of MicroScint0. The radioactivity is counted by a TopCount scintillation counter. IC50 values are calculated by nonlinear regression analysis of the percent inhibitions.

細胞アッセイ: [1]

細胞株 BT-474
濃度 Dissolved in DMSO, final concentrations ~10 μM
反応時間 5 days
実験の流れ The cells are treated continuously with various concentrations of TAK-285 for 5 days. The live cell numbers are counted with a particle analyzer.

動物実験: [1]

動物モデル Female BALB/c nu/nu mice bearing BT-474 or 4-1ST xenografts, and female nude rats (F344/N Jcl-rnu) bearing 4-1ST xenografts
製剤 Suspended in 0.5% (w/v) methylcellulose solution
投薬量 ~100 mg/kg/day
投与方法 Orally twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download TAK-285 SDF
分子量 547.96


CAS No. 871026-44-7
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 110 mg/mL (200.74 mM)
Ethanol 54 mg/mL (98.54 mM)
Water <1 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related EGFR 阻害剤

  • Erlotinib

    Erlotinibは一種のEGFR阻害剤で、このIC50値が2 nMです。Erlotinibは、EGFRに対する敏感性は人間c-Src或いはv-Abに対する敏感性より1000倍以上が高くなります。

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) DimaleateはEGFR/HER2(EGFR(wt)、EGFR(L858R)、EGFR(L858R/T790M) とHER2を含める)を不可逆的に抑制して、IC50値が0.5 nM、0.4 nM、10 nMと14 nMにそれぞれ分かれて、EGFR/HER2に作用する活性はGefitinib抵抗体L858R-T790M EGFRの突然変異体に作用する活性より100倍が高くなります。

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B)は一種の不可逆的で、pan-HER阻害剤で、HER1、HER2とHER4に作用する時のIC50値が3.2 nM、5.3 nMと23.5 nMに分かれることです。臨床2期。

  • AZ5104

    AZ5104はAZD-9291の脱メチル(demethylate)代謝物で、一種の有効なEGFR阻害剤です。AZ5104はEGFR (L858R/T790M、EGFR (L858R)、EGFR (L861Q)とEGFR (野生型)に作用する時のIC50値が1 nM以下、6 nM、1 nMと25 nMにそれぞれ分かれます。臨床1期。

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839)は一種のEGFR阻害剤で、NR6wtEGFRとNR6Wの細胞中のTyr1173、Tyr992、Tyr1173とTyr992に作用する時のIC50値が37 nM、37nM、26 nMと57 nMにそれぞれ分かれることです。

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744)は一種のEGFR阻害剤で、無細胞試験で、IC50値が2 nMです。Erlotinib HCl (OSI-744)はEGFRに作用する選択性は人間c-Src或いはv-Ablに作用する選択性より1000倍以上が高くなります。

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992)はEGFR/HER2( EGFR(wt)、EGFR(L858R)、EGFR(L858R/T790M) とHER2を含める)を不可逆に抑制して、無細胞試験でIC50値が0.5 nM,0.4 nM,10 nM 和 14 nMにそれえぞれ分かれることです。

  • AZD9291

    Osimertinib (AZD9291)は一種の経口不可逆的で、突然変異的で、選択性的なEGFR阻害剤で、 LoVo細胞の中にExon 19欠失のEGFR、L858R/T790M EGFRとWT EGFRに作用する時のIC50値が12.92、11.44と493.8 nMにそれぞれ分かれることです。臨床3期。

  • Lapatinib

    LapatinibはLapatinib Ditosylateの形で使用されて、一種の有効なEGFRとErbB2阻害剤で、無細胞試験で、IC50値が10.8と9.2 nMに分かれることです。

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42)は一種のEGFR阻害剤で、無細胞試験でIC50値が0.1μMになって、EGFRに作用する選択性はErbB2に作用する選択性より135倍が高くなって、JAK2にも抑制作用を表しても、Lck、Lyn、Btk、SykとSrcに抑制活性を表しません。


Tags: TAK-285を買う | TAK-285供給者 | TAK-285を購入する | TAK-285費用 | TAK-285生産者 | オーダーTAK-285 | TAK-285代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID